CL-PTL-119: Double-Blind, Placebo Controlled Phase III Trial of Maintenance FANG (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) for High Risk Stage III/IV Ovarian Cancer
Research Grant
Administered By
Duke Cancer Institute
Awarded By
Gradalis, Inc.
Start Date
August 1, 2015
End Date
September 30, 2023
Administered By
Duke Cancer Institute
Awarded By
Gradalis, Inc.
Start Date
August 1, 2015
End Date
September 30, 2023